172 related articles for article (PubMed ID: 19080742)
1. Molecular profiling in glioblastoma: prelude to personalized treatment.
Mladkova N; Chakravarti A
Curr Oncol Rep; 2009 Jan; 11(1):53-61. PubMed ID: 19080742
[TBL] [Abstract][Full Text] [Related]
2. Pathology: commonly monitored glioblastoma markers: EFGR, EGFRvIII, PTEN, and MGMT.
Camara-Quintana JQ; Nitta RT; Li G
Neurosurg Clin N Am; 2012 Apr; 23(2):237-46, viii. PubMed ID: 22440867
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of MGMT methylation and expression of MGMT, P53, EGFR, MDM2 and PTEN in glioblastoma multiforme.
Limam S; Missaoui N; Abdessayed N; Mestiri S; Selmi B; Mokni M; Yacoubi MT
Ann Biol Clin (Paris); 2019 Jun; 77(3):307-317. PubMed ID: 31131831
[TBL] [Abstract][Full Text] [Related]
4. Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?
Hegi ME; Stupp R
Neuro Oncol; 2015 Nov; 17(11):1425-7. PubMed ID: 26374690
[No Abstract] [Full Text] [Related]
5. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
6. Implications of Dll4-Notch signaling activation in primary glioblastoma multiforme.
El Hindy N; Keyvani K; Pagenstecher A; Dammann P; Sandalcioglu IE; Sure U; Zhu Y
Neuro Oncol; 2013 Oct; 15(10):1366-78. PubMed ID: 23787764
[TBL] [Abstract][Full Text] [Related]
7. A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival.
Das P; Puri T; Jha P; Pathak P; Joshi N; Suri V; Sharma MC; Sharma BS; Mahapatra AK; Suri A; Sarkar C
J Clin Neurosci; 2011 Jan; 18(1):66-70. PubMed ID: 20888234
[TBL] [Abstract][Full Text] [Related]
8. Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas.
Gessler F; Bernstock JD; Braczynski A; Lescher S; Baumgarten P; Harter PN; Mittelbronn M; Wu T; Seifert V; Senft C
Neurosurgery; 2019 Jan; 84(1):190-197. PubMed ID: 29617848
[TBL] [Abstract][Full Text] [Related]
9. MGMT promoter methylation is not correlated with integrin expression in malignant gliomas: clarifying recent clinical trial results.
Schnell O; Albrecht V; Pfirrmann D; Eigenbrod S; Krebs B; Romagna A; Siller S; Giese A; Tonn JC; Schichor C
Med Oncol; 2018 Jun; 35(7):103. PubMed ID: 29882028
[TBL] [Abstract][Full Text] [Related]
10. A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status.
Vázquez-Blomquist D; Leenstra S; van der Kaaij M; Villarreal A; Bello-Rivero I
Mol Biol Rep; 2020 Jul; 47(7):5263-5271. PubMed ID: 32607953
[TBL] [Abstract][Full Text] [Related]
11. Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival.
Schaff LR; Yan D; Thyparambil S; Tian Y; Cecchi F; Rosenblum M; Reiner AS; Panageas KS; Hembrough T; Lin AL
J Neurooncol; 2020 Jan; 146(1):163-170. PubMed ID: 31823165
[TBL] [Abstract][Full Text] [Related]
12. TERT Promoter Mutations Correlate with IDHs, MGMT and EGFR in Glioblastoma Multiforme.
Tomar MS; Shrivastava A
Neurol India; 2021; 69(1):135-136. PubMed ID: 33642284
[No Abstract] [Full Text] [Related]
13. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ
Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives.
Szopa W; Burley TA; Kramer-Marek G; Kaspera W
Biomed Res Int; 2017; 2017():8013575. PubMed ID: 28316990
[TBL] [Abstract][Full Text] [Related]
15. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
Rapkins RW; Wang F; Nguyen HN; Cloughesy TF; Lai A; Ha W; Nowak AK; Hitchins MP; McDonald KL
Neuro Oncol; 2015 Dec; 17(12):1589-98. PubMed ID: 25910840
[TBL] [Abstract][Full Text] [Related]
16. The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients.
McDonald KL; Rapkins RW; Olivier J; Zhao L; Nozue K; Lu D; Tiwari S; Kuroiwa-Trzmielina J; Brewer J; Wheeler HR; Hitchins MP
Eur J Cancer; 2013 Jan; 49(2):360-8. PubMed ID: 22975219
[TBL] [Abstract][Full Text] [Related]
17. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
[TBL] [Abstract][Full Text] [Related]
18. Radiomics signature: A potential biomarker for the prediction of MGMT promoter methylation in glioblastoma.
Xi YB; Guo F; Xu ZL; Li C; Wei W; Tian P; Liu TT; Liu L; Chen G; Ye J; Cheng G; Cui LB; Zhang HJ; Qin W; Yin H
J Magn Reson Imaging; 2018 May; 47(5):1380-1387. PubMed ID: 28926163
[TBL] [Abstract][Full Text] [Related]
19. Association between response to primary treatments and MGMT status in glioblastoma.
Franceschi E; Tosoni A; Pozzati E; Brandes AA
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1781-6. PubMed ID: 18983238
[TBL] [Abstract][Full Text] [Related]
20. Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics.
Jiang S; Rui Q; Wang Y; Heo HY; Zou T; Yu H; Zhang Y; Wang X; Du Y; Wen X; Chen F; Wang J; Eberhart CG; Zhou J; Wen Z
Eur Radiol; 2018 May; 28(5):2115-2123. PubMed ID: 29234914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
